Key facts
- It has raised $1.4M.
- Notable investors include Ben Franklin Technology Partners of Southeastern Pennsylvania, BioAdvance Capital (Conshohocken), HiveBio, The Innovation Space.
- Ajaya Bio has filed 1 Form D with the SEC, most recently Jul 2024 ($150K sold to 2 investors).
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Ajaya Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Ajaya Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Ajaya Bio
Operator of a biotechnology company intended to precisely eliminate disease-driving cells in autoimmune and cancer. The company is tackling the lack of curative therapies in autoimmune and cancer by developing bispecific antibodies that precisely target and eliminate disease-driving cells, enabling the healthcare sector to transform chronic management into potentially curative treatments.
- Sector
- Healthcare
- HQ
- Philadelphia, PA, United States
- Founded
- 2024
- Employees
- 4
- Website
- ajaya.bio/
- Ownership
- Privately Held (backing)
Ajaya Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ajaya Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ajaya Bio in its N-PORT filings yet. We sweep new filings monthly.